Men with obesity who took a GLP-1 drug saw their risk of developing an obesity-related cancer drop by nearly 70%. That number, drawn from a large 2026 study comparing over 160,000 people, is striking enough on its own. What makes it more striking is that the participants didn’t have diabetes – the condition these drugs were originally designed to treat.
GLP-1 receptor agonists (glucagon-like peptide-1 drugs, a class of medications that mimic a gut hormone to regulate blood sugar, appetite, and metabolism) have been headline news for years because of how effectively they shrink waistlines. Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound, have become two of the most prescribed medications in the country. But the data coming out of oncology research in 2026 is pushing scientists to ask a much bigger question: are these drugs doing something to cancer that has nothing to do with weight loss at all?
The answer, based on several large studies presented this year, appears to be: possibly yes. Researchers are now piecing together evidence that GLP-1 drugs may directly interfere with how tumors grow, spread, and survive, and the implications of that are reshaping how cancer doctors think about medications that weren’t originally theirs.
Why Obesity and Cancer Are Already Deeply Linked
Being overweight or obese is associated with a higher risk of getting 13 types of cancer, and those cancers make up 40% of all cancers diagnosed in the United States each year, according to the CDC. The list includes breast, colorectal, liver, kidney, endometrial, and pancreatic cancers, among others.
Excess weight creates long-lasting inflammation and higher-than-normal levels of insulin, insulin-like growth factor, and sex hormones – changes that may lead to cancer. These aren’t abstract biological footnotes. They’re the same pathways GLP-1 drugs happen to disrupt when they lower blood sugar, reduce systemic inflammation, and drive down body fat.
That overlap is what first prompted researchers to look at whether GLP-1 users were developing fewer cancers. The early signals were intriguing. By 2026, those signals had grown into some of the largest observational datasets ever assembled on the question.
A 41% Lower GLP-1 Cancer Risk – and That’s Just the Start
The most comprehensive prevention study to date was published in June 2026 in the Annals of Oncology. Led by Arthur Heng-Cheng Hsu, Ph.D., of Houston Methodist Neal Cancer Center, the study compared 80,899 GLP-1 medication users to 80,899 people who received diet or exercise counseling, across 13 cancer types. GLP-1 use was associated with a 41% lower cumulative incidence of obesity-related cancers over a median follow-up of two years, in obese adults who did not have diabetes.
GLP-1 drugs cut the risk of some cancers more effectively than diet and exercise alone – a finding that also featured prominently at the American Society of Clinical Oncology’s 2026 Annual Meeting, held May 29 to June 2 in Chicago. The gender breakdown from the Annals of Oncology study was particularly notable. Among men, the risk of developing an obesity-related cancer dropped by almost 70%, according to a summary published by ASCO Post. For women, the reductions were still meaningful across several cancer types. Endometrial cancer – cancer of the uterine lining – saw a 58% lower risk among GLP-1 users in the same study, according to Medical News Today.
Not all GLP-1 formulations performed equally. Semaglutide, liraglutide, and dulaglutide showed significant effects, while tirzepatide did not reach statistical significance in that analysis – though a separate finding from the same ASCO Post data noted that tirzepatide users showed the greatest reduction in obesity-related cancer incidence among formulations tested in a different dataset.
Stopping Cancer From Spreading
The prevention data is significant. The research presented at the 2026 ASCO Annual Meeting introduced a separate and arguably more urgent question: can GLP-1 drugs stop cancers that already exist from becoming worse?
Real-world data shows that GLP-1 receptor agonists may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. The study that generated those findings, presented by Dr. Mark David Orland of the Taussig Cancer Institute at Cleveland Clinic, examined 12,112 patients with stage I through III cancers. Half had started a GLP-1 drug after their cancer diagnosis; the other half had started a DPP-4 inhibitor (a different class of diabetes medication). Patients were matched for demographics, body mass index, glycemic factors, smoking, comorbidities, cancer screening frequency, oncologic treatments, and concurrent medications.
The metastatic progression numbers were stark. For lung cancer, GLP-1 use was associated with a 50% reduction in metastatic progression, and a 43% reduction for breast cancer, compared to DPP-4 inhibitor users. For colorectal cancer, metastatic progression occurred in 13% of GLP-1 users versus 22% of DPP-4 inhibitor users. For liver cancer, the rates were 19% versus 28%.
These are meaningful real-world differences in whether patients with early-stage cancer progress to stage IV disease – the stage at which treatment options narrow significantly and survival rates drop. Prostate, pancreatic, and kidney cancers showed numerically fewer metastatic events in GLP-1 users, though those results didn’t reach statistical significance.
GLP-1 RA-exposed patients did not have significant safety signals or increased adverse events compared to controls, according to Hematology Advisor’s coverage of the ASCO findings.
The Biology: Beyond Weight Loss
Why would a drug designed to mimic a gut hormone affect tumor progression? Part of the answer may lie in where GLP-1 receptors are actually found in the body.
A 2025 review published in Pharmaceutics by researchers at the University of Illinois Chicago confirmed that GLP-1 receptors are distributed across a wide range of tissues, including pancreatic islets, the nervous system, cardiovascular tissues, kidneys, lungs, and the gastrointestinal tract – far beyond the sites involved in blood sugar control. That broad distribution is part of why the effects of these drugs extend so far beyond weight and metabolism.
Studies in preclinical models suggest that semaglutide and tirzepatide may inhibit tumor development. The anti-cancer effects may be related to both weight-dependent and weight-independent pathways – semaglutide, for example, is associated with a reduction in inflammation and oxidative stress. You can read more about the documented side effects and systemic reach of GLP-1 drugs that researchers are still working to fully characterize.
The ASCO 2026 researchers went a step further, examining whether GLP-1 receptor expression on tumor cells themselves was associated with survival. High GLP-1 receptor expression on tumors was associated with a 33% lower risk of death overall, and a 45% lower mortality risk specifically in breast cancer, according to Oncology Nursing News. GLP-1 receptor expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.
That’s a meaningful distinction. It suggests the GLP-1 signaling pathway itself may play a direct role in how certain tumors behave – separate from any weight-loss effect.
Breast Cancer: A Specific Focus
Breast cancer has emerged as one of the clearest areas of GLP-1 benefit in 2026 research. A retrospective analysis led by Dr. Elizabeth McDonald, a professor of Radiology at the University of Pennsylvania’s Perelman School of Medicine and a breast radiologist at Penn’s Abramson Cancer Center, examined more than 110,000 women between the ages of 45 and 80. Those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not, according to Penn Medicine.
“GLP-1 medications are intriguing from a cancer research perspective because they weren’t designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development,” McDonald said.
Being overweight or obese, particularly after menopause, is a known risk factor for breast cancer, and chronic low-grade inflammation is suspected to play a contributing role – GLP-1 drugs affect both metabolic and inflammatory pathways, which may underpin their potential preventive effect.
The researchers found that GLP-1 treatment was associated with a lower incidence of breast cancer, independent of age, race, ethnicity, BMI, breast density, and diabetes. An effect that persists after controlling for weight and diabetes suggests the drug may be doing something beyond simply reducing a risk factor.
McDonald and collaborators are actively working to build a multisite clinical trial to assess whether GLP-1 medications can lower breast cancer incidence among women at high risk, including those with a history of breast cancer.
Endometrial Cancer and the Combination Approach
Endometrial cancer – cancer of the uterine lining – deserves particular attention. It’s one of the few cancers that has actually increased in incidence in recent decades, driven largely by rising obesity rates.
The 58% reduction in endometrial cancer risk seen in GLP-1 users in the Annals of Oncology study is notable. A separate analysis went further: Pharmacy Times reported that GLP-1 receptor agonists used in combination with a progestin (a synthetic form of progesterone, a hormone used to treat early-stage endometrial cancer) reduced endometrial cancer risk by approximately 66%, compared to progestin alone. That combination approach may point toward a clinical strategy for women at elevated risk.
What This Means for You
Nearly one in eight Americans are currently taking some form of GLP-1 medication, according to a KFF Health Tracking Poll conducted in November 2025. Most of them are taking these drugs for weight loss or blood sugar control, not cancer prevention. The 2026 research doesn’t change that, but it adds important context for conversations with doctors.
The caveat running through all of this research is that these are observational studies, not randomized controlled trials. Observational studies are hypothesis-generating – they identify associations, not causes. Dr. McDonald’s team at Penn, the ASCO researchers, and others are planning or already running prospective trials to determine whether these associations hold up under more rigorous conditions. For people currently taking GLP-1 drugs for any indication, these studies are not a recommendation to take them as cancer prevention without a diabetes or obesity indication. They are a signal that the health benefits of these medications may be broader than previously understood.
For people with obesity who are already managing a GLP-1 prescription, the emerging GLP-1 cancer risk data is worth raising with an oncologist or primary care physician – particularly for those with a family history of breast, colorectal, endometrial, or liver cancer. For people with an existing early-stage cancer diagnosis who happen to have obesity or diabetes, the ASCO 2026 data suggests GLP-1 drugs may be worth discussing as part of a broader treatment conversation. The numbers aren’t small enough to ignore. Five cluster studies at a single oncology conference all pointing in the same direction is a research community catching up to a signal that’s been accumulating for years. Randomized trial data will determine how much of that signal survives scrutiny. Until then, the picture being assembled is one of a class of drugs whose reach inside the human body turns out to be considerably wider than anyone originally designed them for.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Medicare’s $50/month GLP-1 program starts July 1 — here’s exactly who can get it